{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:49:46Z","timestamp":1788371386669,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jtct.2023.05.016","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T02:47:52Z","timestamp":1685069272000},"page":"504.e1-504.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6009-3945","authenticated-orcid":false,"given":"Aneeqa","family":"Zafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagun","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-5456","authenticated-orcid":false,"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-9813","authenticated-orcid":false,"given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.05.016_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.05.016_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.05.016_bib0003","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0004","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jtct.2023.05.016_bib0005","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633\/BMS-986354 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.05.016_bib0006","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0007","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtct.2023.05.016_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1070353","article-title":"Innovation in BCMA CAR-T therapy: building beyond the Model T","volume":"12","author":"Banerjee","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2023.05.016_bib0009","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"43","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.05.016_bib0010","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children\/young adults with relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2023.05.016_bib0011","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.864.864","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004567","article-title":"Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy","volume":"10","author":"Johnson","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.05.016_bib0013","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1080\/10428194.2018.1454595","article-title":"DCEP as a bridge to ongoing therapies for advanced relapsed and\/or refractory multiple myeloma","volume":"59","author":"Yuen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.05.016_bib0014","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.clml.2021.03.013","article-title":"KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma","volume":"21","author":"Alsouqi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2023.05.016_bib0015","doi-asserted-by":"crossref","unstructured":"Kauer J, Sester LS, Kriegsmann K, et al. Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma [e-pub ahead of print]. Hematol Oncol. doi: 10.1002\/hon.3123. Accessed June 26, 2023.","DOI":"10.1002\/hon.3123"},{"key":"10.1016\/j.jtct.2023.05.016_bib0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41409-022-01848-7","article-title":"Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support","volume":"58","author":"Mouhieddine","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.016_bib0017","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5676.5676","article-title":"High-dose cyclophosphamide in highly refractory multiple myeloma patients as a bridge to further novel therapies","volume":"128","author":"Nikonova","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0018","doi-asserted-by":"crossref","first-page":"e961","DOI":"10.1016\/j.clml.2020.07.015","article-title":"Modified hyper-CVAD with proteasome inhibition for multiple myeloma: a single-center retrospective analysis","volume":"20","author":"Narayan","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.05.016_bib0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-137704","article-title":"Hyperfractionated cyclophosphamide-dexamethasone (HyperCy-Dex) with or without carfilzomib (Car) in patients (pts) with multiple myeloma (MM)","volume":"136","author":"Yeung","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clml.2022.12.004","article-title":"Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with daratumumab and\/or carfilzomib for the treatment of relapsed or refractory multiple myeloma: a single-center retrospective analysis","volume":"23","author":"Shank","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2023.05.016_bib0021","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10428190500254216","article-title":"The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains","volume":"47","author":"Pratt","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.05.016_bib0023","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2015.05.004","article-title":"Serum free light chain assessment early after stem cell transplantation as a prognostic factor in multiple myeloma","volume":"15","author":"Barley","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2023.05.016_bib0024","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1182\/blood-2008-02-138602","article-title":"Appraisal of immunoglobulin free light chain as a marker of response","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.05.016_bib0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12376","article-title":"Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR","volume":"93","author":"Hansen","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2023.05.016_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-021-00600-6","article-title":"Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma","volume":"12","author":"Claveau","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.05.016_bib0027","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.05.016_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.05.016_bib0029","doi-asserted-by":"crossref","first-page":"477.e1","DOI":"10.1016\/j.jtct.2021.03.004","article-title":"Early time-to-tocilizumab after B cell maturation antigen-directed CAR-T therapy in myeloma","volume":"27","author":"Banerjee","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2023.05.016_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.05.016_bib0031","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.05.016_bib0032","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12885-023-10824-3","article-title":"Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients","volume":"23","author":"Sanoyan","year":"2023","journal-title":"BMC Cancer"},{"issue":"suppl","key":"10.1016\/j.jtct.2023.05.016_bib0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.HS9.0000829648.85784.e2","article-title":"Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR-T therapy, in patients with relapsed and refractory multiple myeloma: subanalysis of the KarMMa-trial","volume":"6","author":"Rodriguez-Otero","year":"2022","journal-title":"Hemasphere"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672301299X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672301299X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:46Z","timestamp":1763003386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672301299X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S266663672301299X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.05.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}